JPRN-jRCT2051200153已完成1 期
A Phase 1, single-dose and multiple-dose study of DS-2319b inhalation powder to assess the safety and pharmacokinetics of DS-2319a in healthy Japanese subjects (COVID-19)
Inoguchi Akihiro0 个研究点目标入组 76 人开始时间: 2021年3月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •1. Japanese healthy male subjects.
- •2. Age >=20 and <=45 years upon providing informed consent.
- •3. Body mass index (BMI) >=18.5 and <25.0 kg/m2 at screening.
排除标准
- •1. Having a history of hypersensitivity to any drugs or substances, or being idiosyncratic (eg, having penicillin allergy)
- •2. Having alcohol or drug dependence etc.
研究者
相似试验
招募中
1 期
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.ACTRN12620000583943Senz Oncology Pty Ltd50
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioCystic fibrosis with the G551D mutationMedDRA version: 18.1 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003291-77-GBGalapagos NV26
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioEUCTR2015-003291-77-IEGalapagos NV32
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioEUCTR2015-003291-77-DEGalapagos NV32
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioCystic fibrosis with the G551D mutationMedDRA version: 19.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003291-77-CZGalapagos NV32